# CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

> **NCT05896813** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Newly Diagnosed Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** CMOP+Chidamide

## Key facts

- **NCT ID:** NCT05896813
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896813, "CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05896813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*